COVID19 Vaccines Explained

WHICH VACCINE WILL AUSTRALIA USE?

February 2021


Australia’s COVID vaccine rollout scheduled to begin in mid- to late February. Vaccination will commence with workers dealing with international arrivals or quarantine facilities, frontline health workers and those living in aged care or with a disability. Read more: https://theconversation.com/australias-vaccine-rollout-will-now-start-next-month-heres-what-well-need-152612


The Australian Government announced on the 6th Jan 2021, that the first rollout of vaccines will be Pfizer-BioNtech of which the Government has secured 10 million doses. Followed by 50 million doses of Oxford AstraZeneca vaccine produced in Victoria. Each of these vaccines will be subject to approval by the TGA (Therapeutic Goods Association).


WHY ARE WE NOT RUSHING TO START VACCINATING IN AUSTRALIA

The vaccines in the UK and the USA have only received ‘emergency approval’ of the vaccines currently being distributed which means stage 3 trials are not finished but the demand is too great to wait as both countries are in dire situations with increasing COVID-19 cases and though we have active cases currently, our situation is much better controlled. The TGA would rather wait to receive the full trial results before giving approval. This is expected to now in February 2021.


In January 2021, there were more than 200 vaccine candidates around the world, 48 of which are in clinical trials. To see the latest on the vaccine landscape click here: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.


To ensure Australians will have access to COVID-19 vaccines, the federal government established agreements with suppliers of four of the most promising vaccine candidates. The vaccines have been carefully assessed on advice from a Science and Industry Technical Advisory Group.


So far, the vaccines for which Australia are considering include the AstraZeneca/University of Oxford vaccine, the Novavax vaccine, and the Pfizer/BioNTech vaccine. There is also possibly the Novavax vaccine which is still in phase 3 trials which is manufactured in the USA.


One big question surrounding all of the coronavirus vaccines, is whether they prevent asymptomatic infections as well as illness caused by the virus. Reducing asymptomatic infections, when people can spread the virus without knowing they have it, could have a big impact on slowing the spread of the disease. The Oxford data found some evidence of reduced asymptomatic infections in those who received the half-dose followed by a full dose later.


No one knows for how long coronavirus vaccine provides protection. Some vaccines are effective for years, but for obvious reasons this will take longer to confirm.

 


Read more: What do we know about the Novavax and Pfizer COVID vaccines

 

The Pfizer/BioNTech vaccine, which is currently being administered in the UK, is chemically made - using genetic material. These vaccines are created using new technology, known as mRNA, which introduces a genetic code the body can use to make its own viral protein to induce an immune response. 



These agreements will only progress in Australia should the vaccines prove safe and effective, as assessed by the TGA, which will look at the quality of the vaccine, the degree of protection it offers, and its safety. At this stage, the TGA have not approved either vaccine to be administered in Australia.


Read More: Information from WHO re vaccine development

Read more: The AstraZeneca Oxford University Vaccine


 

REACTION - REPORT OF SEVERE ALLERGIES REPORTED FROM THE UK

10th December 2020: Britain's medical regulator has warned that people with a history of serious allergic reactions should not get the COVID-19 vaccine from Pfizer and BioNTech


Key points:

  • People with a history of severe allergic reactions to vaccine, medicine or food are now being told to not take the vaccine
  • This advice is not uncommon as several vaccines already on the market carry warnings about allergic reactions and subsequent precautionary measures such as the use of ‘epipen’ or having the vaccination is facilities which have resuscitation equipment
  • Late-stage vaccine trials in the UK found "no serious safety concerns"
  • The medical director of the NHS in England says both affected patients are recovering

 

WHY KEEP PFIZER/BIONTECH SUPERCOLD?

The most important challenge for development of a mRNA vaccine remains its inherent instability, because it is more likely to break apart above freezing temperatures.


The vaccine needs to be stored at -80 degrees until the last few days, then stored in a vaccine suitable fridge. Dosage is recommended as 2 doses 21 days apart


VACCINATIONS FOR CHILDREN under 12 – UPDATE

The vaccine is being tested in adults 18-54 years of age, 55-85 years of age and adolescents 12-18 years of age. The Pfizer/BioNTech vaccine is the first COVID-19 vaccine to be tested in adolescents.


There is no COVID-19 vaccine being developed specifically for children. So if children are to be vaccinated, they will likely receive the same vaccine as adults.


Children might require a different dosing schedule, but that is not yet clear. The way a child’s immune system reacts to pathogens or vaccines can be different to adults. Age can determine the number of required doses. For example, infants sometimes require more doses of a vaccine than older children. Age can also influence the side-effect profile of a vaccine. For example, mild fever following vaccination can be common in babies and young children.


Vaccine trials are usually done in stages. They typically start with healthy, young and middle-aged adults.


Once a vaccine is confirmed to be safe in these earlier trials, developers then test the vaccine in older and younger age groups.


There are no protocols yet including children in COVID-19 vaccine trials run in Australia. Any Australian studies would only likely examine the immune response and safety in children (phase 1 and 2 trials). They would probably not examine effectiveness (phase 3 trials) because of the low rates of COVID-19 here.

  • Researchers will need to examine the dosages, interval between doses, and the number of doses which work best in children.
  • This process could take several months
  • Kids may not have an approved vaccine until middle or late 2021.

 

UPDATE RE COVID-19 VACCINE DISTRIBUTION

The ATAGI has provided preliminary advice regarding COVID-19 vaccines strategy for procurement and program delivery for 2021. This document discusses efficacy, duration or protection, targeted groups and modes of delivery. As a summary, those identified as high risk are a priority.

 

UPDATE AS TO WHO IS PRIORITY TO RECEIVE THESE VACCINES?

The Australian COVID-19 Vaccination Policy, endorsed by the National Cabinet on 13 November 2020 discusses the Federal Government selecting and purchasing the vaccines, decide who gets the vaccines and set the standards for the immunisation program.


State and Territory governments will deliver the immunisation program from specified locations. On page 12 it says: Workplace vaccinations: Some larger corporations and high-risk workplaces may establish workplace vaccination clinics in partnership with State and Territory health services or private providers.

While we are still to see what NSW Health decides and what is the most effective and efficient way for our workforce to receive vaccinations, there is no formal approval from Australia to begin a roll out, as approval must first be sought from the TGA (Therapeutic Goods Administration).  It will be interesting to see how the UK responds. Herd immunity isn’t really a consideration for entire population as the BioNTech-Pfizer COVID-19 Vaccine is possible not suitable for children under 12 at this stage. Possible more doses for at risk groups such as those who are immunocompromised. For further information regarding this vaccine, see link from the Australian Government. 

By Glen July 8, 2026
There's a particular kind of quiet that anyone who works in film, television or sport knows well. It's the quiet after the wrap. After the season ends. After the contract runs its course and the next one hasn't landed yet. The gear is packed away, the group chat goes still, and for the first time in weeks or months, the phone doesn't ring. If you've felt that quiet lately, you're not alone. And you're not doing anything wrong. The gap isn't a failure. It's the shape of the work. We tend to talk about these industries as though steady employment is the norm and the quiet stretches are some kind of interruption. For most people who actually make sport and screen happen, it's the other way around. The work comes in bursts. A production. A tour. A season. An event. And in between those bursts sit the gaps — sometimes short, sometimes long, almost always uncertain. This is true whether you're crew waiting on the next shoot or a physio, a medic, a coach or event staff waiting on the next season to start. Plenty of people assume the off-season is paid downtime. For a great many, it isn't. It's the same waiting, the same not-knowing, just with a different name on it. Knowing all this intellectually doesn't make it easier to live through. But it does change one important thing: the gap stops being evidence that something's wrong with you, and starts being what it actually is — a normal part of a professional cycle you've chosen, and chosen for good reasons. It's the not-knowing, not the resting Here's something worth sitting with. Most people who struggle in the gaps aren't actually struggling with the rest. A break, in itself, is fine — good, even. What wears people down is the uncertainty wrapped around it. The open-ended question of when. The quiet arithmetic running in the background about how long the money lasts. The strange loss of identity that comes when so much of who you are is tied to being on set or on the sideline, and suddenly you're neither. That's the real weight of the space between. Naming it honestly is the first step to carrying it better. Getting through it None of what follows is a magic fix. The gaps are real and so is the stress. But over years spent on sets and sidelines, watching how people move through these stretches, a few things consistently seem to help. Protect your routine, especially sleep. When there's nowhere you have to be, structure is the first thing to go — and it's one of the first things to protect. You don't need a rigid schedule. You need enough of a rhythm that your days don't blur and your sleep doesn't drift. Your body and your head both hold up better for it. Deal with the money stress honestly, not silently. The financial worry doesn't get smaller by being ignored; it just gets heavier and quieter. Look at the actual numbers. Make a plan for the lean weeks. Talk to someone if you need to. Certainty about your situation — even uncomfortable certainty — is easier to carry than a vague, growing dread. Stay connected to your people. The instinct when work dries up is often to go quiet, to withdraw, sometimes out of a bit of shame. Resist it. The community that got you your last job is the same one that hears about the next. Beyond the practical side, these are the people who understand exactly what this stretch feels like, because they're living it too. Keep yourself current. Certifications, tickets, skills, fitness — the quiet time is when they slip, and it's also the time you actually have to keep them sharp. Using a gap to stay ready means that when the call comes, you say yes without hesitation. Use the time — but don't punish yourself for resting in it. There's a balance here. Yes, the gap is a chance to learn something, tidy the loose ends, prepare. But it's also, genuinely, permission to breathe after a demanding run. You don't have to earn your rest by being relentlessly productive through it. The mindset that helps most The single most useful shift we've seen people make is this: treating the gap as part of the job, rather than a break from it. The waiting, the preparing, the looking-after-yourself between engagements — that's not time off from your career. That's your career, in its quieter phase. When you hold it that way, the quiet stops feeling like a verdict on your worth. It becomes what it is: the natural in-breath between one demanding stretch and the next. And the phone does ring again It's easy, in the middle of a long gap, to quietly believe this one might be permanent. It rarely is. The industries we work in run in cycles, and the people who look after themselves through the quiet — who keep their rhythm, their relationships and their readiness intact — are the ones who come back sharpest when things pick up again. And they always do pick up again. We spend our working lives looking after the people who make sport and screen happen — on set, on the sidelines, and, we hope, a little in the space between too. Look after yourself out there. We'll all be back at it before long.
By glen March 14, 2025
Burnout is a growing concern in many industries, and the television production world is no exception. With tight deadlines, long hours, and high-pressure environments, production teams are often at risk. However, one overlooked factor in preventing burnout is workplace safety. Safety protocols are not only about physical protection but also about creating a healthy, balanced work environment that reduces stress, boosts morale, and ultimately helps prevent burnout.
By glen March 14, 2025
Whether it's a live concert, a film shoot, or a major sporting event, safety is a top priority. In high-stakes environments where large crowds, complex logistics, and high-pressure situations are the norm, the role of a skilled and experienced safety supervisor is essential. Their expertise ensures the safety of both staff and the public, while also minimizing the impact of emergencies should they arise.